Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at an initial public offering price of $16.00 per share.
Read MoreRoughly 30 pinball machines fill a barn in north Longmont. A handful were made decades ago, with themes ranging from “The Lord of the Rings” to “Godzilla” to “Wheel of Fortune.” Many are considered collector’s items and are worth thousands of dollars.
“I’ve played all these games many times,” said 19-year-old Escher Lefkoff, the top-ranked player in the world by the International Flipper Pinball Association. “Every game is different.”
Read MoreMineralys Therapeutics has penciled in a $100 million initial public offering to take its investigational hypertension drug into Phase III testing.
The Philadelphia startup released topline results for its hypertension drug, dubbed MLS-101 or lorundrostat, two months ago, saying it met the primary endpoint of reducing systolic blood pressure for patients who were on at least two background medicines.
Read MoreLOVELAND, Colo., Jan. 3, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products and solutions, today announced the completion of acquisition of 100% of the shares of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in planar waveguide fluorescence immunoassay diagnostics with strong manufacturing capabilities and research and development expertise (the "Acquisition").
Read MoreMike Arnold grew up ski racing in Maine, discovered backcountry in Colorado and now works as a professional mountain guide in Italy’s Aosta Valley. Surrounded by 4,000-metre alpine peaks, his adopted home is the historical home of ski mountaineering. In this tight-knit local community, guides have always been highly respected. But they face high risks, too.
Having gained so much from the mountains, Mike has recently been forced to come to terms with what they can take away. He is paid to do what he loves but is it worth the risk?
Read MoreWashington, DC. — December 7, 2022 — TerraGo, a leader in smart city and utility infrastructure maintenance solutions, announced that the City of Chicago’s deployment of TerraGo’s streetlight operations software was selected as the winner of a 2022 World Smart City Award.
Read MorePHILADELPHIA, Nov. 16, 2022 /PRNewswire/ -- Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a novel therapy for the treatment of hypertension and associated cardiovascular diseases, today announced topline results from the Phase 2 Target-HTN trial in individuals with uncontrolled and resistant hypertension. MLS-101, a highly selective investigational aldosterone synthase inhibitor, at doses of 50 mg and 100 mg once daily (QD), met its primary endpoint with statistically significant and clinically meaningful reduction in systolic blood pressure (SBP) in inadequately controlled hypertensive patients on at least two background antihypertensive medications.
Read MoreSTERLING, Va. — The Business Intelligence Group named TerraGo StreetlightOps as Product of the Year in the 2022 Sustainability Awards program. TerraGo’s StreetlightOps software is being used to deploy and manage smart LED streetlight networks, replacing inefficient legacy lighting on some of the largest smart city and utility projects around the world.
Read MoreThe American Institute for Avalanche Research and Education (AIARE) just released its 2021-22 Annual Report. Please see the full document linked here: AIARE Annual Report - 2021-22
Read More
